Accessibility Statement Skip Navigation
  • PRNewswire.com
  • Resources
  • +91 22-69790010
  • Client Login
  • Send a Release
PR Newswire: news distribution, targeting and monitoring
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please use Advanced Search to search all press releases.
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • Telephone

    • +91 22-69790010 from 9 AM - 5:30 PM IST

    • Contact
    • Contact

      +91 22-69790010
      from 9 AM - 5:30 PM IST

  • Request More Information
  • Journalists
  • Request More Information
  • Journalists
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Request More Information
  • Journalists
  • Request More Information
  • Journalists

Cintex Services, LLC and Senores Pharmaceuticals, Inc. launch Chlorzoxazone Tablets USP, 250 mg in the U.S. market
  • USA - English


News provided by

Senores Pharmaceuticals, Inc.

05 Oct, 2021, 18:00 IST

Share this article

Share toX

Share this article

Share toX

ATLANTA, Oct. 5, 2021 /PRNewswire/ -- Cintex Services, LLC and Senores Pharmaceuticals, Inc. announce the launch of Chlorzoxazone Tablets USP, 250 mg, a therapeutic equivalent version of Paraflex (Chlorzoxazone) 250 mg in the U.S. market. The product will be distributed by Cintex Services, LLC.

Chlorzoxazone is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions.

Continue Reading
Cintex Services, LLC and Senores Pharmaceuticals, Inc. launch Chlorzoxazone Tablets USP, 250 mg in the U.S. market
Cintex Services, LLC and Senores Pharmaceuticals, Inc. launch Chlorzoxazone Tablets USP, 250 mg in the U.S. market

Senores Pharmaceuticals, Inc. has been granted a competitive generic therapy (CGT) designation for Chlorzoxazone Tablets USP, 250 mg, therefore, with this approval, Senores is the first approved applicant for such competitive generic therapy and is eligible for 180 days of CGT exclusivity upon commercial marketing. 

"We are pleased to announce the commercial launch of Chlorzoxazone Tablets USP, 250 mg in the U.S. through our marketing partner," stated Dhananjay Barot, Director, Senores Pharmaceuticals, Inc. "We'll continue our efforts to be a significant and reliable supplier of this product," stated Swapnil Shah, Managing Director, Senores Group.

 "We are excited about this launch," stated Suzanne Miller, General Manager of Cintex Services, LLC. "We are pleased to partner with Senores to create access for this product and expand our basket of offerings in the U.S. market."

U.S. annual market size for Chlorzoxazone Tablets USP, 250 mg was approximately US$83 million.

About Senores Pharmaceuticals, Inc. 

Senores Pharmaceuticals, Inc., based in Georgia, USA is one of the fastest growing pharmaceutical companies in the U.S. market. Currently, the company has more than 15 products commercially launched or filed with the USFDA.

For more information about Senores Pharmaceuticals, Inc., please visit  www.senorespharma.com

About Cintex Services, LLC

Cintex Services, LLC, based in Georgia, USA, is a generic pharmaceutical provider of over-the-counter (OTC) and FDA approved products. With over 10 products currently marketed, Cintex continues to grow and provide low-cost alternatives for consumers.

Photo: https://mma.prnewswire.com/media/1652902/Cintex_Senores_Pharma.jpg

Modal title

Contact PR Newswire

  • +91 22-69790010

Global Sites

  • APAC
  • APAC - Traditional Chinese
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany

 

  • India
  • Indonesia
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland

 

  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921
Global Sites
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States
+91 (0) 22 6169 6000
from 9 AM - 5:30 PM IST
  • Terms of Use
  • Privacy Policy
  • GDPR
  • Information Security Policy
  • Site Map
  • Cookie Settings
Copyright © 2025 Cision US Inc.